References

medalphabet

Медицинский алфавит

Medical alphabet

2078-56312949-2807

ООО «Альфмед»

10.33667/2078-5631-2021-9-12-15

medalphabet-2029

Research Article

ОБЗОР ЛИТЕРАТУРЫ

Оценка качества жизни пациентов с акне тяжелой степени

Assessment of quality of life in patients with severe acne

https://orcid.org/0000-0003-3437-5233

Грязева

Н. В.

Gryazeva

N. V.

Грязева Наталья Владимировна, к. м. н., доцент кафедрыдерматовенерологии и косметологии

Gryazeva Natalia V., PhD Med, associate prof. at Dept of Dermatovenerology and Cosmetology

tynrik@yandex.ru

https://orcid.org/0000-0002-4672-697X

Тамразова

А. В.

Tamrazova

A. V.

Тамразова Анаит Вардановна, ординатор кафедры дерматовенерологии и косметологии

Tamrazova Anahit V., resident of Dept of Dermatovenerology and Cosmetology

anaittamrazova@gmail.com

ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента РоссииРоссияCentral State Medical Academy of the Administrative Department of the President of RussiaRussian Federation

2021

23062021

Дерматология (1)

1115

2021

Грязева Н.В., Тамразова А.В.

Gryazeva N.V., Tamrazova A.V.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-alphabet.com/jour/article/view/2029

Вульгарные угри являются распространенным заболеванием, поражающим до 85 % подростков. Локализация дерматоза в косметически значимых зонах, длительность течения и формирование симптомов постакне оказывают высокую психоэмоциональную нагрузку и негативно сказываются на качестве жизни. Ввиду того что акне поражает самую уязвимую и зависимую от социальной оценки возрастную группу, крайне важно не пропустить психологические отклонения, такие как тревога, депрессия и суицидальные мысли. В данном обзоре представлены виды диагностических шкал для оценки качества жизни пациентов с акне, патогенез и факторы риска образования рубцов – главного фактора, влияющего на самооценку пациентов с вульгарными угрями, а также предложены новые способы комбинированной терапии с использование кортикостероидов и изотретиноина при лечении тяжелых форм.

Acne vulgaris is a common disease affecting up to 85 % of adolescents. Localization of dermatosis in cosmetically signifiant areas, the duration of the therapy and the formation of post-acne symptoms have a high psycho-emotional load and negatively affect the quality of life. Due to the fact that acne affects the most vulnerable and socially sensitive age group, it is imperative not to overlook psychological abnormalities such as anxiety, depression and suicidal thoughts. This review presents the types of diagnostic scales for assessing the quality of life of patients with acne, pathogenesis and risk factors for scar formation – the main factor affecting the self-esteem of patients with acne vulgaris, and also proposed new methods of combination therapy with the use of corticosteroids and isotretinoin in the treatment of severe forms.

акнетяжелые формы акнекачество жизниДИКЖрубцыизотретиноинкортикостероидыпреднизолон

acnesevere acnequality of lifeDLQIacne scarsisotretinoincorticosteroidsprednisolone

References1

Strauss JS, Krowchuk DP, Leyden JJ, Lucky AW, Shalita AR, Siegfried EC et al.; American Academy of Dermatology / American Academy of Dermatology Association. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007 Apr; 56 (4): 651–63. DOI: 10.1016/j.jaad.2006.08.048. Epub 2007 Feb 5. PMID:17276540.

Lynn DD, Umari T, Dunnick CA, Dellavalle RP. The epidemiology of acne vulgaris in late adolescence. Adolesc Health Med Ther. 2016 Jan 19; 7: 13–25. DOI: 10.2147/AHMT.S 55832. PMID: 26955297; PMCID: PMC 4769025.

Makrantonaki E, Ganceviciene R, Zouboulis C. An update on the role of the sebaceous gland in the pathogenesis of acne. Dermatoendocrinol. 2011 Jan; 3 (1): 41–9. DOI: 10.4161/derm.3.1.13900. PMID: 21519409; PMCID: PMC 3051853.

Kurokawa I, Danby FW, Ju Q, Wang X, Xiang LF, Xia L et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol. 2009 Oct; 18 (10): 821–32. DOI: 10.1111/j.1600–0625.2009.00890.x. Epub 2009 Jun 23. PMID: 19555434.

Kim J, Ochoa MT, Krutzik SR, Takeuchi O, Uematsu S, Legaspi AJ et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol. 2002 Aug 1; 169 (3): 1535–41. DOI: 10.4049/jimmunol.169.3.1535. PMID: 12133981; PMCID: PMC 4636337.

Клинические рекомендации: Акне вульгарные. Российское общество дермато-венерологов и косметологов. 2020. 33 с.

Clinical guidelines: Acne vulgaris. Russian Society of Dermatovenerologists and Cosmetologists. 2020. 33 p.

Sood S, Jafferany M, Vinaya Kumar S. Depression, psychiatric comorbidities, and psychosocial implications associated with acne vulgaris. J Cosmet Dermatol. 2020 Dec; 19 (12): 3177–3182. DOI: 10.1111/jocd.13753. Epub 2020 Oct15. PMID: 33006820.

Sulzberger MB, Zaidens SH. Psychogenic factors in dermatologic disorders. Med Clin North Am. 1948 May; 32: 669–85. DOI: 10.1016/s0025–7125(16)35686–3. PMID: 18857202.

Gollnick HP, Finlay AY, Shear N; Global Alliance to Improve Outcomes in Acne. Can we define acne as a chronic disease? If so, how and when? Am J Clin Dermatol. 2008; 9 (5): 279–84. DOI: 10.2165/00128071–200809050–00001. PMID: 18717602.

Samuels DV, Rosenthal R, Lin R, Chaudhari S, Natsuaki MN. Acne vulgaris and risk of depression and anxiety: A meta-analytic review. J Am Acad Dermatol. 2020 Aug; 83 (2): 532–541. DOI: 10.1016/j.jaad.2020.02.040. Epub 2020 Feb20. PMID: 32088269.

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May; 19 (3): 210–6. DOI: 10.1111/j.1365–2230.1994.tb01167.x. PMID: 8033378.

Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995 Jun; 132 (6): 942–9. DOI: 10.1111/j.1365–2133.1995.tb16953.x. PMID: 7662573.

Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997 Nov; 133 (11): 1433–40. PMID: 9371029.

Motley RJ, Finlay AY. How much disability is caused by acne? Clin Exp Dermatol. 1989 May; 14 (3): 194–8. DOI: 10.1111/j.1365–2230.1989.tb00930.x. PMID: 2531637.

Motley RJ, Finlay AY. Practical use of a disability index in the routine management of acne. Clin Exp Dermatol. 1992 Jan; 17 (1): 1–3. DOI: 10.1111/j.1365–2230.1992.tb02521.x. PMID: 1424249.

Girman CJ, Hartmaier S, Thiboutot D, Johnson J, Barber B, DeMuro-Mercon C, Waldstreicher J. Evaluating health-related quality of life in patients with facial acne: development of a self-administered questionnaire for clinical trials. Qual Life Res. 1996 Oct; 5 (5): 481–90. DOI: 10.1007/BF00540020. PMID: 8973127.

Tan J, Fung KY, Khan S. Condensation and validation of a 4-item index of the Acne-QoL. Qual Life Res. 2006 Sep; 15 (7): 1203–10. DOI: 10.1007/s11136–006–0063–3. Epub 2006 Sep 13. PMID: 16972158.

Gupta MA, Johnson AM, Gupta AK. The development of an Acne Quality of Life scale: reliability, validity, and relation to subjective acne severity in mild to moderate acne vulgaris. Acta Derm Venereol. 1998 Nov; 78 (6): 451–6. DOI: 10.1080/000155598442773. PMID: 9833047.

Rapp SR, Feldman SR, Graham G, Fleischer AB, Brenes G, Dailey M. The Acne Quality of Life Index (Acne-QOLI): development and validation of a brief instrument. Am J Clin Dermatol. 2006; 7 (3): 185–92. DOI: 10.2165/00128071–200607030–00005. PMID: 16734506.

Layton AM, Seukeran D, Cunliffe WJ. Scarred for life? Dermatology. 1997; 195 Suppl 1: 15–21; discussion 38–40. DOI: 10.1159/000246015. PMID: 9310741.

Alexis A, Daniels SR, Johnson N, Pompilus F, Burgess SM, Harper JC. Development of a new patient-reported outcome measure for facial acne: the Acne Symptom and Impact Scale (ASIS). J Drugs Dermatol. 2014 Mar; 13 (3): 333–40. PMID:24595580.

McLellan C, Frey MP, Thiboutot D, Layton A, Chren MM, Tan J. Development of a Comprehensive Quality-of-Life Measure for Facial and Torso Acne. J Cutan Med Surg. 2018 May/Jun; 22 (3): 304–311. DOI: 10.1177/1203475418756379. Epub 2018 Jan 31. PMID: 29383947.

Marron SE, Chernyshov PV, Tomas-Aragones L. Quality-of-Life Research in Acne Vulgaris: Current Status and Future Directions. Am J Clin Dermatol. 2019 Aug; 20 (4): 527–538. DOI: 10.1007/s40257–019–00438–6. PMID: 30949881.

Gupta A, Sharma YK, Dash KN, Chaudhari ND, Jethani S. Quality of life in acne vulgaris: Relationship to clinical severity and demographic data. Indian J Dermatol Venereol Leprol. 2016 May-Jun; 82 (3): 292–7. DOI: 10.4103/0378–6323.173593. PMID: 27088931.

Tan JK, Tang J, Fung K, Gupta AK, Richard Thomas D, Sapra S, et al. Development and validation of a Scale for Acne Scar Severity (SCAR-S) of the face and trunk. J Cutan Med Surg. 2010 Jul-Aug; 14 (4): 156–60. DOI: 10.2310/7750.2010.09037. PMID: 20642983.

Chuah SY, Goh CL. The Impact of Post-Acne Scars on the Quality of Life Among Young Adults in Singapore. J Cutan Aesthet Surg. 2015 Jul-Sep; 8 (3): 153–8. DOI: 10.4103/0974–2077.167272. PMID:26644739; PMCID: PMC 4645145.

Wolfram D, Tzankov A, Pülzl P, Piza-Katzer H. Hypertrophic scars and keloids – a review of their pathophysiology, risk factors, and therapeutic management. Dermatol Surg. 2009 Feb; 35 (2): 171–81. DOI: 10.1111/j.1524–4725.2008.34406.x. PMID: 19215252.

Martin P, Leibovich SJ. Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol. 2005 Nov; 15 (11): 599–607. DOI: 10.1016/j.tcb.2005.09.002. Epub 2005 Oct 3. PMID: 16202600.

Stadelmann WK, Digenis AG, Tobin GR. Physiology and healing dynamics of chronic cutaneous wounds. Am J Surg. 1998 Aug; 176 (2A Suppl): 26S-38S. DOI: 10.1016/s0002–9610(98)00183–4. PMID: 9777970.

Midwood KS, Williams LV, Schwarzbauer JE. Tissue repair and the dynamics of the extracellular matrix. Int J Biochem Cell Biol. 2004 Jun; 36 (6): 1031–7. DOI: 10.1016/j.biocel.2003.12.003. PMID: 15094118.

Тамразова О. Б. Применение репарантов в комплексной терапии хронических дерматозов. Аллергология и иммунология в педиатрии. 2016; 4 (47): 30–37.

Tamrazova O. B. The use of reparants in the complex therapy of chronic dermatoses. Allergology and immunology in pediatrics. 2016; 4 (47): 30–37.

Chivot M, Pawin H, Beylot C, Chosidow O, Dreno B, Faure M et al.; GROUPE EXPERTS ACNE. Cicatrices d’acné: épidémiologie, physiopathologie, clinique, traitement [Acne scars: epidemiology, physiopathology, clinical features and treatment]. Ann Dermatol Venereol. 2006 Oct; 133 (10): 813–24. French. DOI: 10.1016/s0151–9638(06)71053–5. PMID: 17072207.33. Goodman G. Acne and acne scarring – the case for active and early intervention. Aust Fam Physician. 2006 Jul; 35 (7): 503–4. PMID: 16820822.

Agrawal DA, Khunger N. A Morphological Study of Acne Scarring and Its Relationship between Severity and Treatment of Active Acne. J Cutan Aesthet Surg. 2020 Jul-Sep; 13(3):210–216. doi:10.4103/JCAS.JCAS_177_19. PMID: 33208997; PMCID: PMC 7646434.

Holland DB, Jeremy AH, Roberts SG, Seukeran DC, Layton AM, Cunliffe WJ. Inflammation in acne scarring: a comparison of the responses in lesions from patients prone and not prone to scar. Br J Dermatol. 2004 Jan; 150 (1): 72–81. DOI: 10.1111/j.1365–2133.2004.05749.x. PMID: 14746619.

Tan J, Tanghetti E, Baldwin H, Stein Gold L, Lain E. The Role of Topical Retinoids in Prevention and Treatment of Atrophic Acne Scarring: Understanding the Importance of Early Effective Treatment. J Drugs Dermatol. 2019 Mar 1; 18 (3): 255–260. PMID: 30909329.

Ott F, Bollag W, Geiger JM. Oral 9-cis-retinoic acid versus 13-cis-retinoic acid in acne therapy. Dermatology. 1996; 193 (2): 124–6. DOI: 10.1159/000246226. PMID: 8884148.

Nelson AM, Gilliland KL, Cong Z, Thiboutot DM. 13-cis Retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes. J Invest Dermatol. 2006 Oct; 126 (10): 2178–89. DOI: 10.1038/sj.jid.5700289. Epub 2006 Mar 30. PMID: 16575387.

King K, Jones DH, Daltrey DC, Cunliffe WJ. A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population. Br J Dermatol. 1982 Nov; 107 (5): 583–90. DOI: 10.1111/j.1365–2133.1982.tb00410.x. PMID: 6215056.

Falcon RH, Lee WL, Shalita AR, Suntharalingam K, Fikrig SM. In vitro effect of isotretinoin on monocyte chemotaxis. J Invest Dermatol. 1986 May; 86 (5): 550–2. DOI: 10.1111/1523–1747.ep12355006. PMID: 3462263.

Thiboutot DM, Dréno B, Abanmi A, Alexis AF, Araviiskaia E, Barona Cabal MI et al. Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2018 Feb; 78 (2 Suppl 1): S 1–S 23.e1. DOI: 10.1016/j.jaad.2017.09.078. Epub 2017 Nov 8. PMID:29127053.

Evaristo LSBF, Bagatin E. Use of oral isotretinoin to treat acne in the public system: a hospital-based retrospective cohort. Sao Paulo Med J. 2019 Oct 31; 137 (4): 363–368. DOI: 10.1590/1516–3180.2018.054405072019. PMID: 31691769.

Bauer LB, Ornelas JN, Elston DM, Alikhan A. Isotretinoin: controversies, facts, and recommendations. Expert Rev Clin Pharmacol. 2016 Nov; 9 (11): 1435–1442. DOI: 10.1080/17512433.2016.1213629. Epub 2016 Jul 29. PMID: 27414637.

Layton A. The use of isotretinoin in acne. Dermatoendocrinol. 2009 May; 1 (3): 162–9. DOI: 10.4161/derm.1.3.9364. PMID: 20436884; PMCID: PMC 2835909.

Rademaker M. Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us? Australas J Dermatol. 2013; 54 (3): 157–62. PMID: 23013115; DOI: 10.1111/j.1440–0960.2012.00947.x.

Cohen J, Adams S, Patten S. No association found between patients receiving isotretinoin for acne and the development of depression in a Canadian prospective cohort. Can J Clin Pharmacol. 2007 Summer; 14 (2): e227–33. Epub 2007 Jun 6. PMID: 17556790.

Zeynep Demircay, Sadiye Kus, Haydar Sur. Predictive factors for acne flare during isotretinoin treatment. European Journal of Dermatology. 2008; 18 (4): 452–456. DOI: 10.1684/ejd.2008.0441.

Cuellar-Barboza AB, Cárdenas-de la Garza JA, Martínez-Moreno A, et al. Corticosteroid therapy in patients with acne. Dermatol Rev Mex. 2018; 62 (6): 506–515.

Chivot M. Retinoid therapy for acne. A comparative review. Am J Clin Dermatol. 2005; 6 (1): 13–9. DOI: 10.2165/00128071–200506010–00002. PMID: 15675886

The authors declare that there are no conflicts of interest present.